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zzUBACKGROUND Catheter ablation reduces ventricular tachycardia (VT) recurrence and implantable cardioverter
deﬁbrillator shocks in patients with VT and ischemic cardiomyopathy. The most effective catheter ablation technique is
unknown.
OBJECTIVES This study determined rates of VT recurrence in patients undergoing ablation limited to clinical VT along
with mappable VTs (“clinical ablation”) versus substrate-based ablation.
METHODS Subjects with ischemic cardiomyopathy and hemodynamically tolerated VT were randomized to clinical
ablation (n ¼ 60) versus substrate-based ablation that targeted all “abnormal” electrograms in the scar (n ¼ 58). Primary
endpoint was recurrence of VT. Secondary endpoints included periprocedural complications, 12-month mortality, and
rehospitalizations.
RESULTS At 12-month follow-up, 9 (15.5%) and 29 (48.3%) patients had VT recurrence in substrate-based and clinical
VT ablation groups, respectively (log-rank p < 0.001). More patients undergoing clinical VT ablation (58%) were on
antiarrhythmic drugs after ablation versus substrate-based ablation (12%; p < 0.001). Seven (12%) patients with
substrate ablation and 19 (32%) with clinical ablation required rehospitalization (p ¼ 0.014). Overall 12-month mortality
was 11.9%; 8.6% in substrate ablation and 15.0% in clinical ablation groups, respectively (log-rank p ¼ 0.21). Combined
incidence of rehospitalization and mortality was signiﬁcantly lower with substrate ablation (p ¼ 0.003). Periprocedural
complications were similar in both groups (p ¼ 0.61).
CONCLUSIONS An extensive substrate-based ablation approach is superior to ablation targeting only clinical and stable
VTs in patients with ischemic cardiomyopathy presenting with tolerated VT. (Ablation of Clinical Ventricular Tachycardia
Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation (VISTA); NCT01045668) (J Am Coll
Cardiol 2015;66:2872–82) © 2015 by the American College of Cardiology Foundation.I schemic cardiomyopathy (IC) is the most preva-lent cause of ventricular arrhythmias leading tosudden cardiac death in Western countries. Ven-
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AB BR E V I A T I O N S
AND ACRONYM S
AADs = antiarrhythmic drugs
HR = hazard ratio
IC = ischemic cardiomyopathy
ICD = implantable
cardioverter-deﬁbrillator
LV = left ventricle
LVEF = left ventricular
J A C C V O L . 6 6 , N O . 2 5 , 2 0 1 5 Di Biase et al.
D E C E M B E R 2 9 , 2 0 1 5 : 2 8 7 2 – 8 2 VT Ablation in Ischemic Patients
2873are associated with decreased quality of life and
increased mortality (3–6).
Catheter ablation and antiarrhythmic drugs (AADs)
are used to reduce ICD shocks and potentially
improve survival rates in patients with IC and VT.
AADs have shown limited improvement on survival
and suboptimal beneﬁts on ICD shock reduction (3).
Amiodarone reduced shocks by 70% versus beta-
blockade alone in the OPTIC trial, but it is often
associated with serious side effects (6).SEE PAGE 2883
ejection fraction
3D = three-dimensional
VT = ventricular tachycardiaRadiofrequency catheter ablation is effective for
the treatment of drug-refractory and clinically stable
VTs in patients with IC, although recurrence rates
remain high (7–10). Three-dimensional (3D) mapping
systems, open irrigated catheters, and the advent of
percutaneous epicardial ablation have improved
overall success rates of these procedures (1,10–12).
Nonrandomized studies have suggested that a
substrate-based ablation is superior to ablation of
clinical and hemodynamically stable VT (13–16).
METHODS
The study enrolled 118 patients who had received an
ICD before the ablation and suffered from recurrent
stable monomorphic VTs that were symptomatic or
required ICD therapies despite AADs. Between April
2009 and July 2013, patients from 7 centers were
randomized to substrate-based ablation (n ¼ 58) or to
ablation of clinical and mappable VTs only (n ¼ 60)
(Figure 1).
Exclusion criteria included VT that presented with
syncope, loss of consciousness, or cardiac arrest;
age <18 years; severe renal insufﬁciency (glomerular
ﬁltration rate 15 to 29 ml/min/1.73 m2 for $3 months),
left ventricle (LV) thrombus, unstable angina, severe
aortic stenosis, end-stage heart failure with limited
life expectancy, and prior failed VT ablation.
The study was approved by the institutional review
boards of respective participating centers.Mestre Venice, Italy; {{Division of Cardiology, Stanford University, Palo A
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Manuscript received February 27, 2015; revised manuscript received OctobeENDPOINTS. Primary endpoint was recur-
rence of any VT during the 12-month
post-ablation period, as demonstrated by
device interrogation and clinical evaluation.
Secondary endpoints included periprocedural
complications, 12-month post-procedure
mortality, rehospitalization, and combined
incidence of rehospitalization and mortality.
Rehospitalization was deﬁned as a hospital
admission during the post-index procedure
follow-up for arrhythmia-related causes, or
symptoms, signs, or complications of heart
failure.DEFINITIONS. Arrhythmia recurrence was deﬁned as
any arrhythmia receiving device-based treatments
(adenosine triphosphate or shock) or any VT episodes
assessed at clinical evaluation. VTs induced at the
time of ablation were deﬁned as clinical if there was a
match in clinical cycle length, 12-lead electrocardi-
ography (when available), and on the intracardiac
tracings from ICD interrogation when available.
ICDs were uniformly programmed in all patients
and consisted of a VF zone with a cutoff rate of 220
beats per minute and a VT zone of 180 beats per
minute with antitachycardia pacing followed by
shock therapy and a monitor zone that detected the
slowest inducible VT for each patient. A slow VT
window was activated in a monitor-only mode in
patients with known slow VT.
RANDOMIZATION. A central randomization process
with block randomization and 1:1 allocation gener-
ated the randomization list. A computer algorithm
written in SAS version 9.2 (SAS Institute Inc., Cary,
North Carolina) was used for performing block
randomization. To maintain allocation concealment,
the center-level administrators retained the ran-
domization sequence and investigators were not
provided with the upcoming assignment until
patient’s eligibility was conﬁrmed.
ELECTROPHYSIOLOGY STUDY. With the patients
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FIGURE 1 Trial Enrollment and Follow-Up
118 Patients Underwent Randomization
58 Patients were assigned to
Extensive Substrate-based
Ablation
60 Patients were assigned to
Clinical VT Ablation
Followed-up for 12 Months (none lost to follow-up)
58 Patients Included in Primary
Analysis
60 Patients Included in Primary
Analysis
Patients were followed up for 12 months post-ablation. No patient was lost at follow-up during the study period. VT ¼ ventricular tachycardia.
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2874appropriate for the arrhythmia being studied (right
ventricle and LV). LV mapping was performed via the
retrograde aortic or transseptal approach. When
necessary, subxiphoid epicardial access was obtained
by ﬂuoroscopic guidance as previously described (11).
For areas near the phrenic nerve, high-output pacing
was performed from the ablation catheter, and these
locations were marked on the 3D mapping system
and avoided, or when necessary, an esophageal
dilation balloon was used to move the phrenic nerve
from the epicardial surface to allow for ablation with
reduced potential for phrenic nerve injury (17).
3D electroanatomic maps (CARTO, Biosense
Webster, Diamond Bar, California), including voltage
and activation, were obtained in sinus rhythm and/or
during hemodynamically stable VT using a 3.5-mm
open irrigated tip catheter (Thermocool, Biosense
Webster) with the ﬁll threshold setting at 15 mm.
Intracardiac signals were ﬁltered at 30 to 400 Hz.
All patients underwent bipolar substrate mapping
with standard scar settings deﬁned as normal tissue
>1.5 mV and dense scar <0.5 mV. Dense scar was
deﬁned as areas with amplitudes less than or equal to
baseline noise level of the recording system. Maps
included higher density points around areas of scar,
focusing on the scar border and electrograms within
the scar. Normal tissue was less densely mapped.
Areas of fractionated or late potentials were tagged
with color-coded tags to denote the electrogram’stype. These notations were done irrespective of the
voltage obtained.
His bundle electrograms were tagged with separate
colored-coded tags. Maps were considered complete
when the entire chamber of interest was completely
mapped and all scar borders were clearly deﬁned.
Intracardiac echocardiography assisted in deﬁning
mechanical structures, monitoring for potential
complications, and performing transseptal punctures.
Ablation was performed at individual sites for$60 s
at #50 W with a temperature limit of 40C. Systemic
anticoagulation was achieved with intravenous hepa-
rin targeted to a minimum activation clotting time of
300 s. Epicardial access was obtained after anti-
coagulation reversal with protamine in patients
without coronary artery bypass graft or prior sternot-
omy and when clinical VTs were still inducible after
endocardial ablation was concluded. Epicardial 3D
electroanatomic mapping was performed in patients
undergoing epicardial access.
CLINICAL VT ABLATION. Conventional mapping
techniques (pace-mapping, activation mapping, and
entrainment mapping) were used to deﬁne the mech-
anism of the arrhythmias and identify potential sites
for ablation. After complete substratemapping, pacing
protocolswere used to induce clinical VT. Programmed
ventricular stimulation was performed using #3
extrastimuli to refractoriness from 2 different right
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2875ventricle sites. Burst pacing and medications for
provocation, such as intravenous isoproterenol (up to
5 mg/min), were used as necessary.
If clinical tachycardias were not inducible, pacing
was performed from within the scar. After induction
of clinical VT, a complete activation map was per-
formed if the VT was hemodynamically tolerated. The
earliest activation was deﬁned in reference to a sur-
face electrocardiogram lead. Entrainment mapping
and pace mapping conﬁrmed appropriate ablation
sites within the critical isthmus. In patients who did
not tolerate clinical VT, activation mapping was
limited to the area near the scar, and pace-mapping
was used to determine appropriate exit sites.
Entrainment mapping was also used if possible.
Clinical VT and hemodynamically stable, mappable
VTs were targeted for ablation. Nonclinical VTs were
targeted for ablation if stable or if they had
morphology similar to the clinical one. Unstable
nonclinical tachycardias were not targeted for
ablation.
Ablation was performed at the optimal ablation
sites based on the previously mentioned criteria,
preferentially in tachycardia to observe cycle length
slowing and termination. Potential channels withinFIGURE 2 Clinical VT Ablation Approach During VT
(A) Bipolar voltage map of the endocardial left ventricle. Red regions re
normal myocardium (bipolar voltage, 1.5 mV). Other colored regions repr
1.5 mV). Red dots display ablation point across the VT isthmus. (B) Con
415 ms. From top to bottom, 12-lead electrocardiogram of the clinical V
during mapping with the ablation catheter recording (ABLp proximal and
earlier than QRS (red arrow). From top to bottom, 12-lead electrocardio
VT ¼ ventricular tachycardia.the scar were identiﬁed by substrate mapping and
targeted only when conﬁrmed to be involved in the
VT circuits by entrainment mapping (Figures 2A to
2C). Linear ablation lesions were placed to transect
the VT isthmus and terminate inducible VTs. If clin-
ical VT was not tolerated, hemodynamic support with
percutaneous LV-assist device was used at the
discretion of the physician. At the end of the ablation,
programmed stimulation with and without isopro-
terenol was performed in all cases to test the induc-
ibility of VAs. If clinical VTs remained inducible after
endocardial ablation, epicardial mapping and abla-
tion were considered.
SUBSTRATE-BASED ABLATION. Voltage and activa-
tion mapping were as previously described. Careful
identiﬁcation of fractionated, delayed, or abnormal
electrograms was performed. VT induction was not
required in this group. Ablation was never performed
in VT, and induction was only used as the
post-ablation endpoint.
Ablation lesions were empirically extended
throughout the entire scar based on the substrate map
deﬁned by 3D mapping and targeting any abnormal
potentials in normal sinus rhythm. Electrograms were
monitored during ablation to ensure reduction inpresent scar (bipolar voltage, 0.5 mV), and purple regions represent
esent abnormal myocardial regions (bipolar voltage between 0.5 and
cealed entrainment of the clinical VT with a post-pacing interval of
T. (C) Twelve-lead electrocardiogram of the clinical VT (410 ms)
ABLd distal at the site of ablation in the isthmus). The ABLd is 73 ms
gram and ablation catheter recording (proximal to distal).
FIGURE
Endocar
myocard
scar und
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2876amplitude to the noise level except for the border
region. Ablation was continued until abnormal and
late potentials were extinguished. The endpoint in
the substrate-based ablation group was elimination of
all abnormal potentials. This was documented by the
absence or signiﬁcant modiﬁcation of these potentials
as assessed by visual inspection and by non-
inducibility after elimination or modiﬁcation of all
abnormal potentials. Abnormal potentials were usu-
ally deﬁned as fractionated electrograms and/or late
potentials. At the end of the ablation session, pro-
grammed stimulation with and/or without isoproter-
enol (up to 5 mg/min) was performed in all cases to
test the inducibility of any VAs following extensive
substrate ablation. The areas of abnormal potentials
were remapped after ablation to ensure that they
were modiﬁed (Figure 3).
In cases where clinical VTs were inducible after
endocardial ablation, epicardial mapping and ablation
were considered. After substrate ablation, high output
pacing at 20 mA from within the scar was per-
formed to conﬁrm that no tissue could be captured.3 Substrate-Based Ablation Approach in Sinus Rhythm
dial bipolar voltage map of the left ventricle. Red regions represent scar (bi
ium (bipolar voltage, 1.5 mV). Other colored regions represent abnormal myo
erwent extensive substrate-based ablation (red dots). Electrograms of repre
ctrogram recording, 12-lead electrocardiogram leads and electrogram on prox
represents RF application in the area of the scar with abnormal electrogramFOLLOW-UP. All patients were followed at 3-month
intervals with remote monitoring or ofﬁce visits
where implantable devices were interrogated and
during any symptomatic event. One expert electro-
physiologist per center, who was blinded to the
intervention group, reviewed the stored ICD electro-
grams and adjudicated the arrhythmic events.
Arrhythmia recurrence was deﬁned as any symptom-
atic arrhythmia or arrhythmia receiving device-based
treatments (adenosine triphosphate or shock).
Following ablation, all AADs were discontinued and
reinitiated for recurrent VT when applicable.
STATISTICAL ANALYSIS. Using log-rank test, the
study was designed to detect at least 25% reduction in
recurrence rate (50% to 25%) at 12-month follow-up
(hazard ratio [HR]: 0.415; null hazard 0.057) at
2-sided type I error (alpha) of 0.05, and 80% power. A
total of 116 patients (58 per group) were required to
provide the power.
Continuous data were described as mean 
standard deviation (median and interquartile rangepolar voltage, 0.5 mV), and purple regions represent normal
cardial regions (bipolar voltage between 0.5 and 1.5 mV). The entire
sentative endocardial mapping sites are shown with white arrows. In
imal (Carto P) and distal (Carto D) ablation catheter are shown. Each
s as explained in the Methods section.
TABLE 1 Baseline and Procedural Characteristics of
Study Population
Extensive
Substrate-Based
Ablation
(n ¼ 58)
Clinically Stable
VT Ablation
(n ¼ 60) p Value
Age, yrs 67  9 65  12 0.13
Male 54 (93.1) 56 (93.3) 0.96
Hypertension 44 (75.9) 43 (71.7) 0.60
Diabetes 24 (41.7) 19 (31.7) 0.27
BMI 26.4  6.1 24.9  7.2 0.22
NYHA III/IV 31 (53.4) 37 (61.7) 0.37
LVEF 32.0  9.9 32.6  14 0.80
Hyperlipidemia 44 (75.9) 43 (71.7) 0.60
Prior CABG 19 (32.8) 21 (35.0) 0.79
Failed AADs 1.4  0.7 1.5  0.7 0.86
Medications
Sotalol 4 (6.9) 5 (8.3) 1.00
Beta-blocker 46 (79.3) 50 (83.3) 0.57
Mexiletine 5 (8.6) 6 (10.0) 0.68
Nonsustained VT
cycle length
352  86 376  100 0.20
Sustained VT cycle
length
399  86 410  90 0.49
Procedure time, h 4.2  1.3 4.6  1.6 0.14
Fluoroscopy time, min 35  32 28  16 0.13
RF time, min 68  21 35  27 <0.001
Values are mean  SD or n (%).
AAD ¼ antiarrhythmic drug; AF ¼ atrial ﬁbrillation; BMI ¼ body mass index;
CABG ¼ coronary artery bypass graft; LVEF ¼ left ventricular ejection fraction;
NYHA ¼ New York Heart Association; RF ¼ radiofrequency; VT ¼ ventricular
tachycardia.
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2877for non-normal data) and as counts and percent if
categorical. Student t test and chi-square tests were
used to compare groups.
Kaplan-Meier methodology was used to assess
survival time and compare recurrence rate between
groups. Time-to-event was deﬁned as time from
procedure to occurrence of outcome event. For
patients event-free at end of the 12-month study
period, duration of survival was censored. Death
from any cause within the 12-month period was
considered for mortality analysis and was censored
at date of death for VT recurrence endpoint. Uni-
variate and multivariate Cox proportional hazards
models were used to identify signiﬁcant predictors
of VT recurrence and death. Proportional hazards
assumption for the covariates was tested by
Schoenfeld residual analysis. Likelihood ratio tests
were performed to test nonlinear relation. HR and
95% conﬁdence intervals (CI) from the Cox model
were reported.
All randomized patients underwent the ablation
procedure and were included in the efﬁcacy analysis.
All tests were 2-sided, and a p value < 0.05 was
considered statistically signiﬁcant. Analyses were
performed using SAS 9.2 (SAS Institute Inc.).
RESULTS
Baseline clinical characteristics and electrophysio-
logic features were not signiﬁcantly different be-
tween the substrate ablation and clinical ablation
groups; mean LV ejection fraction (LVEF) was 32.0 
9.9% and 32.6  14.1% (p ¼ 0.8), and patients failed an
average of 1.4  0.7 and 1.5  0.7 AADs, respectively
(p ¼ 0.86) (Table 1).
PROCEDURAL DATA. Mean cycle length of induced
clinical VTs was 399  86 ms in the substrate-based
ablation group and 410  90 ms in clinical VT
ablation group (p ¼ 0.49). Although pre-ablation
induction was not required in the substrate-based
ablation arm, 22 (38%) patients in this group had
clinically stable VT induction. In the clinical abla-
tion group, the median number of induced clinical
stable VTs was 2. Nonclinical VTs were inducible in
47 (78%) of clinical ablation patients, with an
average of 2.7  1.2 VTs per patient. These VTs had
an average cycle length of 376  100 ms. Sustained
clinical VT was inducible in 59 (98%) patients in
this group. Hemodynamic support was used for 8
patients during catheter ablation because of circu-
latory instability and/or for intolerance to anes-
thesia, and was discontinued at the conclusion of
the procedure.The procedural (4.2  1.3 h and 4.6  1.6 h;
p ¼ 0.14) and ﬂuoroscopy times (35  32 and 28  16
min; p ¼ 0.13) were not statistically different between
substrate-based ablation and clinical ablation groups,
although a trend of longer procedural time was
observed during clinical ablation. However, after
removing substrate-based ablation patients in whom
induction of VT was performed (22 cases), procedural
time decreased to 3.4  1.7 h, which was signiﬁcantly
shorter than in clinical ablation (4.2  1.3 vs. 3.4  1.7;
p ¼ 0.018). Procedural and ﬂuoroscopy times for
these 22 patients were 4.7  0.9 h and 36  18 min,
respectively. Radiofrequency time was substantially
longer in substrate-based ablation (68  21 vs. 35  27
min; p < 0.001) (Table 1).
Elimination of all abnormal potentials within the
scar tissue during substrate-based ablation was not
achieved in 9 (16%) of the cases. In 8 of the cases,
epicardial ablation was not possible because of coro-
nary artery bypass graft.
In the clinical ablation group, epicardial ablation
was performed in 7 (11.7%) patients, whereas it was
performed in 6 of the substrate-based ablation
CENTRAL ILLUSTRATION VT Ablation in Patients With Ischemia
Di Biase, L. et al. J Am Coll Cardiol. 2015; 66(25):2872–82.
The curve compares the cumulative probability of VT recurrence (on or off antiarrhythmic drug) between patients undergoing substrate-based ablation and stable
clinical ablation. Patients with substrate-based ablation exhibited signiﬁcantly lower recurrence rate at 12-month follow-up: 9 of 58 (15.5%) compared with 29 of 60
(48.3%) patients in clinical VT ablation (log-rank p < 0.001). Median time to recurrence was 7.0 months (interquartile range: 6.3 to 7.8 months) and 2.5 months
(interquartile range: 1.2 to 8.6 months), respectively (unadjusted hazard ratio: 0.26 [95% conﬁdence interval: 0.11 to 0.61]). VT ¼ ventricular tachycardia.
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TABLE 2 Summary of Outcomes by Study Groups
Substrate-Based Ablation (%) Clinical Ablation (%) p Value HR (95% CI)
VT recurrence rate 15.5 (8.4–27.7) 48.3 (36.6–61.2) <0.001 0.26 (0.11–0.61)
All-cause mortality rate 8.6 (1.4–14.2) 15.0 (5.9–24.2) 0.21 0.54 (0.17–1.82)
Arrhythmia-related rehospitalization 12.1 (3.8–19.7) 31.7 (22.1–41.6) 0.014 0.31 (0.13–0.78)
Composite: rehospitalization and mortality 20.7 (10.3–30.1) 46.7 (34.0–59.3) 0.003 0.32 (0.17–0.61)
Composite: VT recurrence and mortality 24.1 (13.2–35.1) 63.3 (51.1–75.5) <0.001 0.20 (0.09–0.43)
The summary table presents the event rates (95% conﬁdence interval), p values from log-rank test, and unadjusted hazard ratio for the outcome measures.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; VT ¼ ventricular tachycardia.
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2879patients (10.3%) because of persistent clinical VT
inducibility after endocardial ablation (p ¼ 1.00).
POST-ABLATION INDUCIBILITY AND ICD PROGRAMMING.
After ablation, all patients from the substrate-based
ablation group underwent the same pre-ablation in-
duction protocol as for the clinical ablation group.
Noninducibility of the clinical VTs was achieved in
all patients in both groups. In the clinical ablation
group, the average number of post-ablation unstable
nonclinical VTs induced was lower than what
observed at the beginning (2.0  1.4 vs. 2.7  1.2;
p ¼ 0.011).
Only 3 (5%) patients undergoing clinical VT abla-
tion and 2 (3%) undergoing substrate-based ablation
had the device programmed in a manner that differed
from the protocol-required device programming, but
this was considered appropriate by the implanting
physician (p ¼ 1.00).
FOLLOW-UP. All patients in the study were included
in the survival analysis and none was lost to
follow-up during the study period. At the time of
analysis, all recurrence-free patients had completed
12-month follow-up in both groups.
We observed a nonsigniﬁcant trend toward
improvement in LVEF and New York Heart Associa-
tion functional class at 1 year in substrate-based
ablation patients. LVEF change was 2.4  6.6% in
the substrate-based ablation group versus 2.1  5.8%
in the clinical ablation group (p ¼ 0.13). The number
of patients with New York Heart Association III/IV
decreased from 53.4% to 46.6% in the substrate-
based ablation, and from 61.7% to 53.3% in the
clinical ablation group (p ¼ 0.26).
VT RECURRENCE. Substrate-based ablation was
associated with signiﬁcantly lower VT recurrence
rates at 12-month follow-up compared with clinical
ablation (15.5% vs. 48.3%; log-rank p < 0.001).
Unadjusted HR for recurrence was 0.26 (0.11 to
0.61). Median time to recurrence was 7.0 months
(interquartile range, 6.3 to 7.8) and 2.5 months(interquartile range, 1.2 to 8.6), respectively.
Kaplan-Meier curves comparing cumulative recur-
rence rate on or off AADs are presented in the
Central Illustration. More patients receiving clinical
ablation were on AADs after ablation compared
with substrate-based ablation 58% versus 12%,
respectively (p < 0.001).
REHOSPITALIZATION. Seven (12.1%) in the
substrate-based ablation group and 19 (32%) in the
clinical ablation group required rehospitalization
(p ¼ 0.014). Median time to rehospitalization was
6.5 months and 3.4 months, respectively. Two reho-
spitalizations in the substrate-ablation group and 7
readmissions in the clinical group were VT- and
heart-failure related (p ¼ 0.16).
MORTALITY. Overall mortality during 12-month
follow-up was 11.9%; 5 (8.6%) in the substrate-based
ablation group and 9 (15.0%) in the clinical ablation
group (log-rank p ¼ 0.21). Three patients in the
substrate-based ablation group and 5 in the clinical
VT ablation group died from nonarrhythmic cardio-
vascular causes, mostly from refractory heart failure.
Death from noncardiac causes, including sepsis from
device infection and cancer, occurred in 2 patients
undergoing substrate-based ablation and 4 patients
undergoing clinical VT ablation.
COMBINED REHOSPITALIZATION AND MORTALITY.
The combined incidence of rehospitalization and
mortality was signiﬁcantly lower in substrate-based
ablation (20.7% [95% CI: 10.3% to 30.1%] vs. 46.7%
[95% CI: 34.0% to 59.3%]; p ¼ 0.003). Event rates for
all outcomes and unadjusted HR are summarized in
Table 2.
PROCEDURAL COMPLICATIONS. One arteriovenous
ﬁstula and 5 pericardial effusions occurred in the
overall study population. The arteriovenous ﬁstula
occurred in the clinical ablation group. Three effusions
(5.17%) were reported in the substrate-based ablation
group and 2 (3.33%) in the clinical ablation group
(p ¼ 0.61). All effusions were treated conservatively.
TABLE 3 Univariate and Multivariate Cox Regression Analyses of Potential
Risk Factors for VT Recurrence
Factors Univariate Model Multivariate Model
Predictors of VT
Recurrence HR (95% CI) p Value HR (95% CI) p Value
Age, per 5 yrs 1.11 (1.07–1.53) 0.016 1.09 (0.87–1.63) 0.271
Male 3.23 (1.13–6.28) 0.029 2.53 (0.59–10.75) 0.210
LVEF 0.77 (0.48–0.92) 0.035 1.05 (0.80–1.39) 0.716
Diabetes 3.11 (1.19–8.12) 0.020 2.75 (1.01–7.46) 0.042
Hypertension 1.34 (0.61–2.93) 0.460 1.14 (0.89–1.45) 0.303
No. of VT morphologies 1.01 (0.75–1.37) 0.952 1.04 (0.76–1.42) 0.817
Electrical storm 1.86 (1.06–2.81) 0.043 1.29 (0.95–1.83) 0.102
ICD shocks 2.53 (0.59–7.80) 0.209 2.24 (0.47–10.77) 0.314
Substrate-based
ablation
0.26 (0.11–0.61) 0.001 0.33 (0.13–0.18) 0.014
ICD ¼ implantable cardioverter-deﬁbrillator; other abbreviations as in Tables 1 and 2.
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multivariate association of clinical and procedural
variables are displayed in Table 3. Age (5-year
increments), male sex, electrical storm, LVEF, dia-
betes, and substrate-based ablation showed signiﬁcant
unadjusted association with VT recurrence.
After adjusting for covariates in Cox multivariate
model, substrate-based ablation was associated with
67% lower risk of recurrence compared with clinical
ablation (HR: 0.33 [95% CI: 0.13 to 0.81]; p ¼ 0.014).
Age and LVEF were not associated with recurrence,
whereas history of diabetes (HR: 2.75 [95% conﬁdence
interval: 1.01 to 7.46]; p ¼ 0.042) was an independent
predictor of VT recurrence.
DISCUSSION
This is the ﬁrst randomized multicenter study
showing that substrate-based ablation reduces
recurrence of any VT at follow-up when compared
with ablation limited to clinical and mappable VTs in
patients with IC. Furthermore, combined reduction of
rehospitalization and mortality was observed in the
substrate ablation group. Our study suggests that a
larger area of scar tissue must be ablated to reduce
recurrence from any VTs in patients with IC and sta-
ble clinical VTs. A larger percentage of patients was
able to discontinue AADs after substrate ablation, an
important ﬁnding because AADs can have signiﬁcant
long-term side effects.
Clinical studies have demonstrated the superiority
of radiofrequency catheter ablation compared
with medical therapy in controlling recurrent
post-myocardial infarction VT (18–21). However,
long-term freedom from VT remains an issue, withreported long-term success rates of #55% to 60%
(8–10,22).
Noninducibility of clinical VT by programmed elec-
trical stimulation represents the endpoint endorsed by
current guidelines. However, a direct association be-
tween VT noninducibility and long-term freedom from
any VT has not been uniformly reported (22–24).
Furthermore, the deﬁnition of noninducibility has
been heterogeneous among studies (22–24).
The site of programmed electrical stimulation
might also play a role; some studies have highlighted
the limitation of right ventricular versus LV stimula-
tion for induction of the clinical VT and the impor-
tance of stimulation from areas inside the scar tissue
(23,24).
In the clinical ablation group, the number of in-
duced post-ablation nonclinical VTs was lower. This
may be because some nonclinical VTs may also be
eliminated, due to shared areas of the critical isthmus.
Surviving cardiac ﬁbers within and around the scar
tissue create areas of slow conduction that generate
the arrhythmogenic substrate of ischemic VT (25).
Identiﬁcation of these areas by low-voltage electro-
grams on the mapping catheter is possible in sinus
rhythm and in VT. Mapping during VT may be difﬁ-
cult because of hemodynamic instability (10,13–16).
Identiﬁcation of abnormal electrograms during sinus
rhythm has been linked to critical sites of VT. Abla-
tion of the isthmus responsible for clinical VT is the
technique of choice in this setting (10) despite un-
satisfactory outcomes at long-term follow-up (8–10).
Nonrandomized series have proposed substrate-
based ablation techniques, which target abnormal
electrograms indexing slow conduction (i.e., ab-
normal, split, and late electrograms) in sinus rhythm
as reasonable surrogates of the VT isthmus (13–16).
Experience in cardiac arrhythmia surgery (18)
showed worse results with incomplete elimination
of the scar area by either aneurysmectomy or
endocardial resection (19–21). A possible reason for
the failure of aneurysmectomy is that it did not
include all critical areas of diseased myocardium
responsible for the arrhythmia. Josephson et al. (18)
postulated that the subendocardial Purkinje ﬁbers
that survive myocardial infarction represent a
component of the re-entrant circuit and suggested
subendocardial resection in the area of the earliest
activity as a method of removing the source of the
arrhythmia. In their work, subendocardial resection
was extended to the normal-appearing tissue (26–28).
Other important ﬁndings of our study were that
a higher number of patients discontinued AADs in
the substrate-based ablation group, and substrate
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In patients with
ischemic cardiomyopathy and scar-related, sustained, re-entrant
VT, substrate-based ablation in sinus rhythm is associated with
greater freedom from VT without antiarrhythmic drug therapy
than induction and ablation of clinical VT.
TRANSLATIONAL OUTLOOK: Further studies are needed to
compare the efﬁcacy of various methods of substrate-based
ablation in patients with ischemic cardiomyopathy.
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with shorter overall procedural times.
STUDY LIMITATIONS. Complete elimination of
abnormal potentials within the scar tissue in the
substrate ablation group was not possible in 16% of
the population. We believe this is in part because
epicardial access could not be obtained in patients
with previous coronary artery bypass graft. However,
we still noted an incremental beneﬁt in terms of
arrhythmia-free survival in patients in whom com-
plete elimination of abnormal signals within the scar
could not be achieved. Determination of whether an
induced VT is “clinical” is sometimes difﬁcult
because similarity in cycle lengths and intracardiac
ICD morphologies are imperfect predictors, another
potential limitation.
CONCLUSIONS
This is the ﬁrst randomized trial showing that
substrate-based ablation approach is superior to
ablation targeting only clinical and stable VTs inpatients with IC presenting with tolerated VT and is
associated with a signiﬁcant reduction in the com-
bined endpoint of rehospitalization and mortality.
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